CYCLAVANCE™ (cyclosporine oral solution) USP MODIFIED for canine atopic dermatitis now available

Virbac announces the availability of CYCLAVANCE™ for canine atopic dermatitis treatment (Photo courtesy of Virbac Corporation).

Virbac Corporation has released CYCLAVANCE™ (cyclosporine oral solution) USP MODIFIED, an oral solution for the management of canine atopic dermatitis. Though veterinarians in the United States are familiar with cyclosporine in capsule form, CYCLAVANCE™ oral solution is the first FDA-approved liquid cyclosporine for dogs available in the country.

"Atopic dermatitis in dogs is a common chronic relapsing skin disease characterized by itchy and inflamed skin. The condition can cause discomfort and pain in dogs and often requires lifelong management," said Cristiano von Simson, DVM, MBA, marketing and veterinary services director at Virbac, in a company release.¹

"Recommending a product that is easy for the client to administer correctly can significantly improve the long-term satisfaction with the treatment," he added.

Treatment guidelines from the International Committee on Allergic Diseases of Animals (ICADA) emphasize using a multimodal approach for atopic dermatitis treatment while also including a plan for broad inflammation management.^2,3 Along with removing or avoiding known flare factors, the ICADA Guidelines recommend cyclosporine as part of a multi-faceted approach to controlling acute flare-ups.^2,3

Additionally, CYCLAVANCE™ oral solution has demonstrated higher acceptance rate by dogs when compared to cyclosporine capsules.^3,4 CYCLAVANCE™ oral solution as a liquid formulation has been shown to have a greater than 98% acceptance rate by dogs when administered either directly in the mouth or when combined with a small amount of food.⁴ According to the release, the delivery system also enables precise dosing at 5 mg/kg for all dogs, with greater accuracy than when dosing with capsules.

“The management of atopic dermatitis is complex and our thinking about it has evolved in recent years,” says von Simson. "The ICADA Guidelines acknowledge the importance of cyclosporine as part of a multimodal treatment approach—an approach that includes a plan for managing both inflammation and pruritus.”

CYCLAVANCE™ is for use in dogs only. Wear gloves during and wash hands after administration. Gastrointestinal problems and gingival hyperplasia may occur at the initial recommended dose. The product should be used with caution in cases involving diabetes mellitus (it can cause elevated levels of serum glucose); in dogs with renal insufficiency (the effect of cyclosporine use on dogs with compromised renal function has not been studied); in simultaneous administration with drugs that suppress the P-450 enzyme system (that may lead to increased plasma levels of cyclosporine).

Killed vaccines are recommended for dogs receiving CYCLAVANCE™ because the impact of cyclosporine on the immune response to modified live vaccines has not been evaluated. To receive prescribing information, contact Virbac at 1-800-338-3659 or visit us.virbac.com.

To learn more about CYCLAVANCE™, go here.

References

1. Virbac announces availability of CYCLAVANCE™ (cyclosporine oral solution) USP MODIFIED for atopic dermatitis in dogs. News release. July 23, 2021; Circa Healthcare. Accessed September 7, 2021. https://www.einnews.com/pr_news/547029441/virbac-announces-availability-of-cyclavance-tm-cyclosporine-oral-solution-usp-modified-for-atopic-dermatitis-in-dogs
2. Olivry T, DeBoer DJ, Favrot C, et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol. 2010;21:233-248.
3. Olivry T, DeBoer DJ, Favrot C, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res. 2015;11:210:1–15.
4. Navarro C, Crastes N, Benizeau E, McGahie D. Voluntary acceptance and consumption of two oral ciclosporin formulations in dogs: two randomised, controlled studies. Ir Vet J. 2015;68:3.